Both companies are important suppliers to clinical laboratories and research labs
In recent days, news surfaced that Thermo Fisher Scientific Inc. (NYSE: TMO) was offering $6 billion to acquire Millipore Corporation (NYSE:MIL). Neither company has confirmed the offer, but yesterday Millipore issued a statement that its Directors were “evaluating strategic options.”
Should Thermo Fisher acquire Millipore, or should Millipore find another buyer, it will mean the same thing: more consolidation among vendors who are major suppliers for clinical pathology laboratories. This would continue a global consolidation trend among clinical laboratory suppliers and in vitro diagnostics (IVD) manufacturers that reaches back more than a decade and a half.